New York, NY -- (SBWIRE) -- 12/26/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Lam Research Corporation (NASDAQ:LRCX), Myriad Genetics, Inc (NASDAQ:MYGN), Questcor Pharmaceuticals Inc (NASDAQ:QCOR), Ambac Financial Group, Inc.(NASDAQ:AMBC)
Lam Research Corporation (NASDAQ:LRCX) showed a volume of 639,376.00 shares by the end of last trade whereas the average volume of the stock remained 1.67 million shares. The stock opened the session at $54.38 but then moved to $54.40. Lam Research Corporation (Lam Research), is a supplier of wafer fabrication equipment and services to the worldwide semiconductor industry. Lam Research designs, manufactures, markets, refurbish, and services semiconductor processing equipment used in the fabrication of integrated circuit. In addition, it offers a broad portfolio of single-wafer clean technologies. Its Customer Support Business Group (CSBG) provides products and services to maximize installed equipment performance and operational efficiency.
Is LRCX a Solid Investment at These Levels? Read This Report For Details
Myriad Genetics, Inc (NASDAQ:MYGN) opened the session at $23.90 and closed the session at $24.18. The stock showed a positive performance of 1.34% in previous trading session. Traded with volume of 639,194.00 shares in the prior session and the average volume of the stock remained 2.39 million shares. Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis.
For How Long MYGN will fight for Profitability? Read This Trend Analysis report
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) opened the session at $53.89 and closed the session at $54.01. The stock showed a positive performance of 0.22% in previous trading session. Traded with volume of 637,165.00 shares in the prior session and the average volume of the stock remained 2.03 million shares. The beta of the stock remained 1.27. Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications;
Why Should Investors Buy QCOR After The Recent Gain? Just Go Here and Find Out
Ambac Financial Group, Inc.(NASDAQ:AMBC) the stock advanced 3.59% and finished the session at $23.98. Traded with volume of 629,293.00 shares in the prior session and the average volume of the stock remained 663,086.00 shares.
Will AMBC Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)